Back to Results

Lexicon Pharmaceuticals Inc (LXRX)

Featured in High-Growth Small-Cap Stocks

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. Its portfolio includes sotagliflozin, an orally delivered small-molecule therapy being developed for hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for type 1 diabetes. The company also markets INPEFA (sotagliflozin), a once-daily oral tablet indicated to help reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Additional development programs include LX9851 for obesity and related cardiometabolic disorders and pilavapadin (LX9211) for neuropathic pain. Lexicon Pharmaceuticals has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. Founded in 1995, it is headquartered in The Woodlands, Texas.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-LXRX
$1.32
-18.1% Downside
Overvalued
$4.46
177.3% Upside
Bargain
Good
0.0%
4.1x
17.3x
720.8 M
585.1 M
8.3%
49.2%
-8.3
106.3%
Valuation • Fair Value

Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) Fair Value by Valuation Model

Review the available estimates for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.32

Estimated downside of 18.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.29

Discounted cash flow valuation reference.

Comps Fair Value

$1.33

Comparable-company valuation reference.

Analyst Price Target

$4.46

Analysts imply upside of 177.3%.

How to read these valuation models

Use the 5 available valuation references for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

41.469 M

Current operating scale indicator.

Revenue Forecast

34.721 M

Forward revenue estimate.

EBITDA

-54.023 M

Current operating profitability reference.

EBITDA Forecast

-66.715 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.56

No elevated caution signal from this screen.

Altman Z-Score

-8.3

Lower score that deserves closer risk review.

FCF / Net Income

106.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) Stock Forecast & Technical Outlook

Review Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) has a Buy consensus, with 3 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 2
Sell 0
FAQ • Fast Investor Answers

Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) Stock FAQ

Data-supported answers about Lexicon Pharmaceuticals Inc (NASDAQ-LXRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.32
Estimated downside 18.1%
Valuation Rating
Overvalued
Estimated downside of 18.1%
Analyst Target
$4.46
Implied upside 177.3%
Financial Health
Good
Current financial-health read

The current fair value estimate for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is $1.32. This implies an estimated downside of 18.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.1% versus the current market price.

The available analyst price target for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is $4.46. The analyst target implies estimated upside of 177.3%.

The current financial health read for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Lexicon Pharmaceuticals Inc (NASDAQ-LXRX).

The current market capitalization listed for Lexicon Pharmaceuticals Inc is 720.8 M.

The current enterprise value listed for Lexicon Pharmaceuticals Inc is 585.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Lexicon Pharmaceuticals Inc is NASDAQ-LXRX, and the stock is listed on NASDAQ.

Lexicon Pharmaceuticals Inc (NASDAQ-LXRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Lexicon Pharmaceuticals Inc is 8.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Lexicon Pharmaceuticals Inc is 49.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B